Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(02): 172-176
DOI: 10.1055/s-0041-1732822
Drug Review

Dasatinib—A Generation Ahead

Subramaniam Murali Carthikeyan
1   Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
Perumal Kalaiyarasi Jayachandran
1   Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
› Author Affiliations Funding There were no external sources of funding for this project.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Dasatinib is a highly potent second-generation (2G) tyrosine kinase inhibitor (TKI) used in the management of Philadelphia (Ph) chromosome-positive leukemias, chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). In CML, dasatinib produces higher rates of early and deeper molecular responses compared with imatinib. The drug has its share of toxicities, namely, cytopenias, cardiovascular, and pleural effusion. This review describes the pharmacological aspects of dasatinib, clinically relevant toxicities, and their management.

Keywords

dasatinib - second-generation TKI in CML - chronic myeloid leukemia


Publication History

Article published online:
05 August 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Nowell PC. The minute chromosome (Phl) in chronic granulocytic leukemia. Blut 1962; 8 (02) 65-66
    CrossrefPubMedGoogle Scholar
  • 2 van Leeuwen RWF, van Gelder T, Mathijssen RHJ, Jansman FGA. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 2014; 15 (08) e315-e36
    CrossrefPubMedGoogle Scholar
  • 3 Porkka K, Koskenvesa P, Lundán T, Rimpilä J, Mustjoki S, Smykla R. et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.. Blood 2008; 112 (04) 1005-12
    CrossrefPubMedGoogle Scholar
  • 4 Dewaele B, Wasag B, Cools J. et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008; 14 (18) 5749-5758
    CrossrefPubMedGoogle Scholar
  • 5 Li J, Zhou Y, Zhang X. et al. Safety and efficacy of dasatinib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib: A single arm, multicenters, phase 2 trial. J Clin Oncol 2019; 37 (Suppl. 04) 138-138
    CrossrefGoogle Scholar
  • 6 Kantarjian H, Shah NP, Hochhaus A. et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362 (24) 2260-2270
    CrossrefPubMedGoogle Scholar
  • 7 Highlights of prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf. Accessed June 30, 2021
  • 8 Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2011; 25 (02) 201-210
    CrossrefPubMedGoogle Scholar
  • 9 Hughes TP, Laneuville P, Rousselot P. et al. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica 2019; 104 (01) 93-101
    CrossrefPubMedGoogle Scholar
  • 10 Cortes JE, Jimenez CA, Mauro MJ, Geyer A, Pinilla-Ibarz J, Smith BD. Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management. Clin Lymphoma Myeloma Leuk 2017; 17 (02) 78-82
    CrossrefPubMedGoogle Scholar
  • 11 Steegmann JL, Baccarani M, Breccia M. et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30 (08) 1648-1671
    CrossrefPubMedGoogle Scholar
  • 12 Kantarjian H, Cortes J, Kim DW. et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009; 113 (25) 6322-6329
    CrossrefPubMedGoogle Scholar
  • 13 Naqvi K, Jabbour E, Skinner J. et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2020; 126 (01) 67-75
    CrossrefPubMedGoogle Scholar
  • 14 Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF. The impact of dasatinib on pregnancy outcomes. Am J Hematol 2015; 90 (12) 1111-1115
    CrossrefPubMedGoogle Scholar
  • 15 Cortes JE, Saglio G, Kantarjian HM. et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-Naïve chronic myeloid leukemia patients trial. J Clin Oncol 2016; 34 (20) 2333-2340
    CrossrefPubMedGoogle Scholar
  • 16 Shen S, Chen X, Cai J. et al. Effect of dasatinib vs imatinib in the treatment of pediatric philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol 2020; 6 (03) 358-366
    CrossrefPubMedGoogle Scholar
  • 17 Shah NP, Rousselot P, Schiffer C. et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol 2016; 91 (09) 869-874
    CrossrefPubMedGoogle Scholar
  • 18 Ottmann O, Saglio G, Apperley JF. et al. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer J 2018; 8 (09) 88
    CrossrefPubMedGoogle Scholar
  • 19 Okada M, Imagawa J, Tanaka H. et al. DADI Trial Group, Japan. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. Clin Lymphoma Myeloma Leuk 2018; 18 (05) 353-360.e1
    CrossrefPubMedGoogle Scholar
  • 20 Shah NP, García-Gutiérrez V, Jiménez-Velasco A. et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma 2020; 61 (03) 650-659
    CrossrefPubMedGoogle Scholar